Crossmark

Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies

Crossref DOI link: https://doi.org/10.1186/s12885-018-4374-x

Published Online: 2018-04-27

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vosoughi, Elham

Lee, Jee Min

Miller, James R.

Nosrati, Mehdi

Minor, David R.

Abendroth, Roy

Lee, John W.

Andrews, Brian T.

Leng, Lewis Z.

Wu, Max

Leong, Stanley P.

Kashani-Sabet, Mohammed

Kim, Kevin B. https://orcid.org/0000-0003-0694-0530
License Information

Text and Data Mining valid from 2018-04-27
More Information

Article History

Received: 21 November 2017

Accepted: 16 April 2018

First Online: 27 April 2018

Ethics approval and consent to participate

: This study protocol was approved by an institutional review board (“Sutter Health Institutional Review Board”, San Francisco, CA, USA), and a waiver of patient consent was obtained prior to initiation of the study.

: David R. minor received honoraria from Bristol-Myer Squibb and Merck; Mohammed Kashani-Sabet received research funding from Merck.; Kevin B. Kim received honoraria from Bristol-Myer Squibb, Merck, Novartis and Genentech. Institution received research grant from Bristol-Myer Squibb, Merck and Novartis.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.